The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

NEXT STORY
10x Genomics to Report Second Quarter Financial Results on August 11, 2020
PREV STORY
CB2 Insights to Host Q1 2020 Earnings Call on July 15, 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results

ROCKVILLE, Md., May 03, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203

– Phase 2a study of MAT2203 for the treatment of mucocutaneous candidiasis infections; Topline ...

author_avatar
NASDAQ Market News

OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech

OSE to pursue clinical development of FR104 to treat autoimmune diseasesFR104’s good phase 1 ...

author_avatar
NASDAQ Market News